COVAX announced new agreement, plans for first deliveries
On Jan. 22, 2021, COVAX, the global initiative to ensure rapid and equitable access to COVID-19 vaccines for…
-
-
Pfizer and BioNTech reached agreement with COVAX for advance purchase of vaccine to combat COVID-19
On Jan. 22, 2021, Pfizer and BioNTech announced an advance purchase agreement with COVAX for up to 40…
-
Pfizer and BioNTech published results of study showing COVID-19 vaccine antibodies neutralized UK strain
On Jan. 19, 2021, Pfizer and BioNTech announced that results from an in vitro study that provided additional…
-
Pfizer and BioNTech announced European scale-up of manufacturing capacities
On Jan. 15, 2021, Pfizer and BioNTech announced they had developed a plan that allowed the scale-up of…
-
In vitro study showed Pfizer-BioNTech COVID-19 vaccine elicited antibodies that neutralize SARS-CoV-2 with mutation
On Jan. 8, 2021, Pfizer and BioNTech announced results from an in vitro study conducted by Pfizer and…
-
BioNTech confirmed EC’s proposal to purchase additional doses of vaccine
On Jan. 8, 2021, BioNTech announced that it was in talks with the European Commission (EC) about an…
-
BioNTech published data on novel mRNA vaccine approach to treat autoimmune diseases in Science
On Jan. 7, 2021, BioNTech announced publication of preclinical data on its novel mRNA vaccine approach against autoimmune…
-
Biotechnology | COVID-19 | Vaccine | WHO
WHO issued its first EUV for a COVID-19 vaccine and emphasized need for equitable global access
On Dec. 31, 2020, the World Health Organization (WHO) listed the Comirnaty COVID-19 mRNA vaccine for emergency use,…
-
Pfizer and BioNTech to supply the US with 100 million additional doses of COVID-19 vaccine
On Dec. 23, 2020, Pfizer and BioNTech announced a second agreement with the U.S. government to supply an…
-
Pfizer and BioNTech received CHMP positive opinion for their COVID-19 vaccine
On Dec. 21, 2020, Pfizer and BioNTech announced that the Committee for Medicinal Products for Human Use (CHMP)…
-
Pfizer and BioNTech received authorization in the European Union for COVID-19 vaccine
On Dec. 21, 2020, Pfizer and BioNTech announced that the European Commission (EC) had granted a conditional marketing…
-
Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATY
On Dec. 19, 2020, Pfizer and BioNTech announced they supplying an additional 100 million doses of COMIRNATY the…
-
BioNTech and Fosun Pharma to supply China with mRNA-based COVID-19 vaccine
On Dec. 16, 2020, BioNTech and Shanghai Fosun Pharmaceutical announced an agreement to supply Mainland China with an…
-
Data from phase 1/2 study further characterized immune response with lead COVID-19 vaccine candidate
On Dec. 14, 2020, Pfizer and BioNTech announced additional data on neutralizing antibody and T cell responses from…
-
CDC recommended vaccination with Pfizer and BioNTech COVID-19 vaccine for ages 16 years and older
On Dec. 12, 2020, Pfizer and BioNTech announced that the CDC’s Advisory Committee on Immunization Practices (ACIP) voted…
-
CDC’s ACIP issued interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine in persons aged =16 years for prevention of COVID-19.
On Dec. 12, 2020, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of…
-
US FDA issued Emergency Use Authorization for first COVID-19 vaccine
On Dec. 11, 2020, the FDA issued the first emergency use authorization (EUA) for a vaccine for the…
-
Pfizer and BioNTech received FDA Advisory Committee vote supporting EUA for COVID-19 vaccine in the US
On Dec. 10, 2020, Pfizer and BioNTech announced that the FDA Vaccines and Related Biological Products Advisory Committee…
-
UK medicines regulator approved first UK COVID-19 vaccine
On Dec. 2, 2020, the first COVID-19 vaccine for the UK, developed by Pfizer/BioNTech, was given approval for…
-
Pfizer and BioNTech achieved first authorization in the world for a vaccine to combat COVID-19
On Dec. 2, 2020, Pfizer and BioNTech announced that the Medicines & Healthcare Products Regulatory Agency (MHRA) in…
-
Pfizer and BioNTech submitted application for Conditional Marketing Authorization for COVID-19 vaccine
On Dec. 1, 2020, Pfizer and BioNTech announced they had submitted on Nov. 30, 2020, a formal Application…
-
BioNTech and Fosun Pharma announced start of phase 2 clinical trial of mRNA COVID-19 vaccine in China
On Nov. 25, 2020, BioNTech and Shanghai Fosun Pharmaceutica jointly announced that their lead mRNA COVID-19 vaccine candidate…
-
BioNTech and InstaDeep announce AI Innovation Lab to develop novel immunotherapies
On Nov. 25, 2020, BioNTech and InstaDeep announced a multi-year strategic collaboration aimed at applying the latest advances…
-
Avian influenza virus spread rapidly in Europe
On Nov. 20, 2020, the ‘European Food Safety Authority reported that within the past month more than 300…
-
Pfizer and BioNTech to submit Emergency Use Authorization Request to the FDA for COVID-19 vaccine
On Nov. 20, 2020, Pfizer and BioNTech announced they submitted a request to the Food and Drug Administration…
-
Pfizer and BioNTech announced phase 3 study of COVID-19 vaccine candidate met all efficacy endpoints
On Nov. 18, 2020, Pfizer and BioNTech announced that, after conducting the final efficacy analysis in their ongoing…
-
BioNTech and Fosun Pharma approved to commence COVID-19 vaccine candidate BNT162b2 trial in China
On Nov. 16, 2020, BioNTech and Shanghai Fosun Pharmaceutica announced that the China National Medical Products Administration had…
-
CureVac’s COVID-19 vaccine candidate, CVnCoV, suitable for standard fridge temperature logistics
On Nov. 12, 2020, CureVac announced that its mRNA-based COVID-19 vaccine candidate, CVnCoV, remained stable and within defined…
-
Pfizer and BioNTech to supply the EU with 200 million doses of mRNA-based vaccine against SARS-CoV-2
On Nov. 11, 2020, Pfizer and BioNTech announced that they had reached an agreement with the European Commission…
-
Pfizer and BioNTech announced vaccine candidate against COVID-19 achieved success in interim analysis from phase 3 study
On Nov. 9, 2020, Pfizer and BioNTech announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 had demonstrated evidence…
